The Initiative for Promoting Affordable and Quality Tests (IPAQT), a consortium of private sector diagnostic laboratories, will now offer the World Health Organisation (WHO)-endorsed GeneXpert HCV and HIV viral load tests at less than 50 per cent of the market price in India.
Diseases in India :-
- India has the third largest HIV (human immunodeficiency virus) epidemic in the world with an estimated burden of over two million.
- HCV (hepatitis C virus) infection is estimated to be as high as 8 to 12 million.
- India accounts for 23 per cent of global tuberculosis (TB) incidence with an estimated 2.2 million cases reported in 2014.
What would be the effect of reducing the cost of diagnostic test ?
- Reducing the cost of these diagnostic tests will enhance accessibility and result in timely diagnosis and improved patient outcomes.
- It will also increase efficiency, save operational costs for labs and diagnostic costs for patients and ultimately improve quality of patient care.
About IQPAT – (Initiative for Promoting Affordable and Quality Tests) :-
- In 2013 :-
With the support from the Clinton Health Access Initiative Inc. (CHAI), some of the largest diagnostic laboratories in India came together to start an Initiative for Promoting Affordable and Quality Tests (IPAQT) and offer TB diagnostic tests at affordable prices.
- Currently, the consortium has almost 200 members who offer WHO-endorsed TB tests, such as GeneXpert, Hain LPA, BacTALERT 3D, and MGIT.
- IPAQT laboratories have increased the adoption of quality TB tests from 28,000 in 2013 to over 2,40,000 tests in 2017.
- IPAQT has been instrumental in providing low cost TB diagnosis using the latest molecular technology in India.